Academic-community hospital comparison of vulnerabilities in door-to-needle process for acute ischemic stroke

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 6_suppl_3, 2015, Pages S148-S154

  Prabhakaran, Shyam ^a,b   Khorzad, Rebeca ^b   Brown, Alexandra ^b   Nannicelli, Anna P ^b   Khare, Rahul ^b   Holl, Jane L ^b  

^a Division of Neurology   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

academic medical center; community hospitals; patient safety; quality improvement; stroke

Indexed keywords

ACADEMIC COMMUNITY HOSPITAL; ARTICLE; BRAIN ISCHEMIA; COMPARATIVE STUDY; CROWDING (AREA); DOOR TO NEEDLE PROCESS; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FIBRINOLYTIC THERAPY; HEALTH CARE QUALITY; HOSPITAL; HUMAN; MEDICAL PROCEDURES; PATIENT SAFETY; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT FAILURE; ACUTE DISEASE; COMMUNITY HOSPITAL; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; ISCHEMIA; STATISTICS AND NUMERICAL DATA; STROKE; TIME TO TREATMENT; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

TISSUE PLASMINOGEN ACTIVATOR;

ACADEMIC MEDICAL CENTERS; ACUTE DISEASE; DIAGNOSTIC ERRORS; DIAGNOSTIC IMAGING; EMERGENCY SERVICE, HOSPITAL; HOSPITALS, COMMUNITY; HUMANS; ISCHEMIA; QUALITY IMPROVEMENT; STROKE; THROMBOLYTIC THERAPY; TIME-TO-TREATMENT; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; TRIAGE;

EID: 84945910642     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.115.002085     Document Type: Article

References (44)

1. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D, ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 359 1317 1329. doi: 10.1056/NEJMoa0804656
2. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995 333 1581 1587
3. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH, Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013 309 2480 2488. doi: 10.1001/jama.2013.6959
4. Agency for Healthcare Research and Quality (AHRQ) Diagnosis and Treatment of Ischemic Stroke: Percentage of Patients With Stroke Symptoms Who Are Candidates for tPA With a "Door To Drug" Time (Time of Arrival to Time of Drug Adminstration) of Less Than 60 Minutes 2012 Agency for Healthcare Research and Quality (AHRQ). http://www.qualitymeasures.ahrq.gov/content.aspx?id=38375&search=tissue+plasminogen. Accessed June 12, 2015
5. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013 44 870 947. doi: 10.1161/STR.0b013e318284056a
6. Fonarow GC, Zhao X, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Xian Y, Hernandez AF, Peterson ED, Schwamm LH, Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014 311 1632 1640. doi: 10.1001/jama.2014.3203
7. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernandez AF, Peterson ED, Sacco RL, Schwamm LH, Improving door-to-needle times in acute ischemic stroke: the design and rationale for the American Heart Association/American Stroke Association's Target: Stroke initiative. Stroke 2011 42 2983 2989. doi: 10.1161/STROKEAHA.111.621342
8. Meretoja A, Weir L, Ugalde M, Yassi N, Yan B, Hand P, Truesdale M, Davis SM, Campbell BC, Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013 81 1071 1076. doi: 10.1212/WNL.0b013e3182a4a4d2
9. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M, Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology 2012 79 306 313. doi: 10.1212/WNL.0b013e31825d6011
10. Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC, Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013 6 543 549. doi: 10.1161/CIRCOUTCOMES.111.000303
11. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Bhatt DL, Grau-Sepulveda MV, Olson DM, Hernandez AF, Peterson ED, Schwamm LH, Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation 2011 123 750 758. doi: 10.1161/CIRCULATIONAHA.110.974675
12. Parikh SV, Jacobi JA, Chu E, Addo TA, Warner JJ, Delaney KA, McGuire DK, deLemos JA, Cigarroa JE, Murphy SA, Keeley EC, Treatment delay in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction: a key process analysis of patient and program factors. Am Heart J 2008 155 290 297. doi: 10.1016/j.ahj.2007.10.021
13. Kelly EW, Kelly JD, Hiestand B, Wells-Kiser K, Starling S, Hoekstra JW, Six Sigma process utilization in reducing door-to-balloon time at a single academic tertiary care center. Prog Cardiovasc Dis 2010 53 219 226. doi: 10.1016/j.pcad.2010.08.002
14. Ford AL, Williams JA, Spencer M, McCammon C, Khoury N, Sampson TR, Panagos P, Lee JM, Reducing door-to-needle times using Toyota's lean manufacturing principles and value stream analysis. Stroke 2012 43 3395 3398. doi: 10.1161/STROKEAHA.112.670687
15. Khare RK, Nannicelli AP, Powell ES, Seivert NP, Adams JG, Holl JL, Use of risk assessment analysis by failure mode, effects, and criticality to reduce door-to-balloon time. Ann Emerg Med 2013 62 388 398.e12. doi: 10.1016/j.annemergmed.2013.01.023
16. Gressel MG, Gideon JA, An overview of process hazard evaluation techniques. Am Ind Hyg Assoc J 1991 52 158 163. doi: 10.1080/15298669191364514
17. Lieberman P, Design FMEA and the industry. Automot Eng 1990 98 31 33
18. The Joint Commission 2001 The Joint Commission. Joint Commission Standards in Support of Patient Safety and Medical/Health Care Error Reductions: Joint Commission Standard ld.5.2
19. Patient Safety Authority Educational tools: Preventing wrong-site surgery. Patient Safety Authority. http://patientsafetyauthority.org/EDUCATIONALTOOLS/PATIENTSAFETYTOOLS/PWSS/Pages/home.aspx. Accessed June 12, 2015
20. Emergency Care Research Institute. An introduction to FMEA. Using failure mode and effects analysis to meet JCAHO's proactive risk assessment requirement. Failure modes and effect analysis. Health Devices 2002 31 223 226
21. Military Standard MIL-STD-1629a Procedures for Performing a Failure Mode, Effects and Criticality Analysis 1980 Washington, DC Department of Defense
22. McElroy L, Khorzad R, Nannicelli A, Brown A, Holl J, Failure mode and effects analysis: a comparison of two common risk prioritization methods. BMJ Qual Saf. Published ahead of print July 13, 2015. doi: 10.1136/bmjqs-2015-004130
23. Automotive Industry Action Group Failure Modes and Effects Analysis (FMEA) Reference Manual 2008 4th ed Chysler LLC, Ford Motor Company, General Motors Corporation; Detroit, MI
24. Automotive Quality and Process Improvement Committee. SAE International Potential failure mode and effects analysis in design (design FMEA), potential failure mode and effects analysis in manufacturing and assembly processes (process FMEA): Standard J1739. 2009. Available at http://standards.sae.org/j1739-200901/
25. Hammond JS, Keeney RL, Raiffa H, The hidden traps in decision making. Harv Bus Rev 1998 76 47 48, 50, 52 passim
26. Graber ML, Medical diagnosis-the promise. Diagnosis 2014 1 5 9
27. Schiff GD, Bates DW, Can electronic clinical documentation help prevent diagnostic errors? N Engl J Med 2010 362 1066 1069. doi: 10.1056/NEJMp0911734
28. DeVon HA, Zrelak P, Nurses trained in the use of the ROSIER tool can assess signs and symptoms of stroke with comparable accuracy to doctors performing standard neurological assessment. Evid Based Nurs 2012 15 64. doi: 10.1136/ebnurs.2011.100300
29. Chiong W, Kim AS, Huang IA, Farahany NA, Josephson SA, Testing the presumption of consent to emergency treatment for acute ischemic stroke. JAMA 2014 311 1689 1691. doi: 10.1001/jama.2014.3302
30. Chiong W, Kim AS, Huang IA, Farahany NA, Josephson SA, Inability to consent does not diminish the desirability of stroke thrombolysis. Ann Neurol 2014 76 296 304. doi: 10.1002/ana.24209
31. Gadhia J, Starkman S, Ovbiagele B, Ali L, Liebeskind D, Saver JL, Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke 2010 41 300 306. doi: 10.1161/STROKEAHA.109.566935
32. Rosenbaum JR, Bravata DM, Concato J, Brass LM, Kim N, Fried TR, Informed consent for thrombolytic therapy for patients with acute ischemic stroke treated in routine clinical practice. Stroke 2004 35 e353 e355. doi: 10.1161/01.STR.0000136555.28503.55
33. White-Bateman SR, Schumacher HC, Sacco RL, Appelbaum PS, Consent for intravenous thrombolysis in acute stroke: review and future directions. Arch Neurol 2007 64 785 792. doi: 10.1001/archneur.64.6.785
34. Chen Y, Bogosavljevic V, Leys D, Jovanovic D, Beslac-Bumbasirevic L, Lucas C, Intravenous thrombolytic therapy in patients with stroke mimics: baseline characteristics and safety profile. Eur J Neurol 2011 18 1246 1250. doi: 10.1111/j.1468-1331.2011.03367.x
35. Giraldo EA, Khalid A, Zand R, Safety of intravenous thrombolysis within 4.5 h of symptom onset in patients with negative post-treatment stroke imaging for cerebral infarction. Neurocrit Care 2011 15 76 79. doi: 10.1007/s12028-011-9523-x
36. Hemmen TM, Meyer BC, McClean TL, Lyden PD, Identification of nonischemic stroke mimics among 411 code strokes at the University of California, San Diego, Stroke Center. J Stroke Cerebrovasc Dis 2008 17 23 25. doi: 10.1016/j.jstrokecerebrovasdis.2007.09.008
37. Uchino K, Massaro L, Hammer MD, Transient ischemic attack after tissue plasminogen activator: aborted stroke or unnecessary stroke therapy? Cerebrovasc Dis 2010 29 57 61. doi: 10.1159/000255975
38. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, Putaala J, Haapaniemi E, Tatlisumak T, Chen Y, Leys D, Sarikaya H, Michel P, Odier C, Berrouschot J, Arnold M, Heldner MR, Zini A, Fioravanti V, Padjen V, Beslac-Bumbasirevic L, Pezzini A, Roos YB, Nederkoorn PJ, Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke 2013 44 1080 1084. doi: 10.1161/STROKEAHA.111.000126
39. Liberman AL, Liotta EM, Caprio FZ, Ruff I, Maas MB, Bernstein RA, Khare R, Bergman D, Prabhakaran S, Do efforts to decrease door-to-needle time risk increasing stroke mimic treatment rates? Neurol Clin Pract 2015 5 247 252. doi: 10.1212/CPJ.0000000000000122
40. Aulicky P, Rabinstein A, Seet RC, Neumann J, Mikulik R, Dosing of tissue plasminogen activator often differs from 0.9 mg/kg, but does not affect the outcome. J Stroke Cerebrovasc Dis 2013 22 1293 1297. doi: 10.1016/j.jstrokecerebrovasdis.2012.10.010
41. Breuer L, Nowe T, Huttner HB, Blinzler C, Kollmar R, Schellinger PD, Schwab S, Köhrmann M, Weight approximation in stroke before thrombolysis: the WAIST-Study: a prospective observational "dose-finding" study. Stroke 2010 41 2867 2871. doi: 10.1161/STROKEAHA.110.578062
42. Graves A, VerHage A, Richlik B, Makic MB, Estimated versus actual weight when dosing rt-PA in acute ischemic stroke: is there a difference? J Neurosci Nurs 2013 45 180 185. doi: 10.1097/JNN.0b013e318298641b
43. Messé SR, Tanne D, Demchuk AM, Cucchiara BL, Levine SR, Kasner SE, Multicenter rt-PA Stroke Survey Group Dosing errors may impact the risk of rt-PA for stroke: the Multicenter rt-PA Acute Stroke Survey. J Stroke Cerebrovasc Dis 2004 13 35 40. doi: 10.1016/j.jstrokecerebrovasdis.2004.01.001
44. Sahlas DJ, Gould L, Swartz RH, Mohammed N, McNicoll-Whiteman R, Naufal F, Oczkowski W, Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes. J Stroke Cerebrovasc Dis 2014 23 155 159. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.004